VXL Share Price Performance

VXL Community Fair Values

View all narratives

Recent VXL News & Updates

No updates

Vaxil Bio Ltd. Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

Earnings per share (EPS): -0.069
Gross Margin: 0%
Net Profit Margin: 0%
Debt/Equity Ratio: 0%

View full report ›

Vaxil Bio Ltd. Competitors

About VXL

Founded: 2006
Employees: n/a
CEO: Gadi Levin
WebsiteView website: vaxil-bio.com

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. The company was founded in 2006 and is headquartered in Toronto, Canada.

Canadian Market Performance

0.7%

13.4%

17.8%

9.9%

The market has been flat in the last week, however the Healthcare sector is down 4.0%. More promisingly, the market is up 18% over the past year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›

Vaxil Bio Stock Price

VXL Share Price Performance

VXL Community Fair Values

Recent VXL News & Updates

Vaxil Bio Ltd. Key Details

Vaxil Bio Ltd. Competitors

Kua Investments

Castlebar Capital

Eureka Capital

Atlas One Capital

Canna 8 Investment Trust

Mayfair Acquisition

Draxos Capital

Mandeville Ventures

🇪🇺 🇬🇧 Momentum Is Returning to European and UK Markets

The Big Beautiful Deficit